A Randomized, Open-Label, Phase III Trial Comparing Adjuvant Trastuzumab Plus Neratinib Versus Trastuzumab Plus Pertuzumab in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Residual Cancer Burden 0/I After Neoadjuvant Trastuzumab Plus Pertuzumab
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Invasive disease free survival, IDFS
研究概览
简要总结
Neratinib is an irreversible pan-HER tyrosine kinase inhibitor (TKI). Currently, no studies have investigated the use of macromolecular anti-HER2 agents combined with TKIs for the treatment of non-pCR HER2-positive breast cancer following neoadjuvant therapy. Furthermore, there are no prospective randomized controlled trials comparing trastuzumab plus pertuzumab versus trastuzumab plus TKIs in HER2-positive breast cancer patients with residual cancer burden class (RCB) I or II after neoadjuvant trastuzumab and pertuzumab. Therefore, this study aimed to evaluate the efficacy and safety of adjuvant trastuzumab plus neratinib in patients with hormone receptor-positive/HER2-positive breast cancer and RCB 0/I following neoadjuvant trastuzumab and pertuzumab therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients aged 18-70 years;
- •Eastern Cooperative Oncology Group performance status of 0 or 1;
- •Clinical stage at initial diagnosis (per the 8th edition of the American Joint Committee on Cancer Staging Manual): cT1-4/N1-3/M0 (cT1mi/N0 or cT1a-b/N0 are eligible), meeting the criteria for neoadjuvant therapy as per NCCN 2022 guidelines;
- •Histologically confirmed hormone receptor-positive (estrogen receptor ≥1% and/or progesterone receptor ≥1%) and HER2-positive (immunohistochemistry 3+ or fluorescence in situ hybridization-positive) invasive breast cancer;
- •Completion of ≥4 cycles of neoadjuvant therapy with trastuzumab and pertuzumab, without recurrence or metastatic disease prior to adjuvant treatment; residual cancer burden class 0 or I after neoadjuvant therapy; time from initial surgery to randomization ≤12 weeks;
- •Adequate organ function within 2 weeks prior to screening (without transfusion or use of growth factors):
- •Absolute neutrophil count ≥1.5 × 10⁹/L;
- •Platelet count ≥90 × 10⁹/L;
- •Hemoglobin ≥90 g/L;
- •Total bilirubin ≤1.5 × upper limit of normal (ULN);
- •Alanine aminotransferase and aspartate aminotransferase ≤1.5 × ULN;
- •Post-neoadjuvant therapy echocardiography showing left ventricular ejection fraction (LVEF) ≥50% during screening, with an absolute decrease of ≤15% compared to pre-chemotherapy values; if no pre-chemotherapy LVEF assessment is available, LVEF must be ≥55% during screening;
- •Life expectancy ≥6 months;
- •For premenopausal or non-sterilized female patients: agreement to abstain from sexual activity or use effective non-hormonal contraception during study treatment and for 8 weeks after the last dose;
- •Willingness to participate voluntarily, provide signed informed consent, demonstrate good compliance, and cooperate with follow-up.
排除标准
- •History of local or regional breast cancer recurrence;
- •Clinical stage IV (metastatic) breast cancer;
- •Bilateral breast cancer;
- •History of other malignant tumors within the past 5 years, except for curatively treated cervical carcinoma in situ, basal cell carcinoma, or cutaneous squamous cell carcinoma;
- •Prior treatment with pyrotinib, lapatinib, neratinib, or other tyrosine kinase inhibitors; trastuzumab emtansine; or any antitumor biological or immunotherapy;
- •Concurrent participation in another clinical trial involving antitumor therapy, including endocrine therapy, bisphosphonate therapy, or immunotherapy;
- •Significant cardiac disease, including:
- •Heart failure or systolic dysfunction (LVEF < 50%);
- •Poorly controlled arrhythmias (e.g., atrial tachycardia, significant ventricular arrhythmia, or high-grade atrioventricular block);
- •Angina requiring antianginal medication;
- •Clinically significant valvular heart disease;
- •Electrocardiographic evidence of transmural myocardial infarction;
- •Poorly controlled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg) despite medication;
- •Impaired drug absorption due to dysphagia, intestinal obstruction, or other gastrointestinal disorders;
- •History of neurological or psychiatric conditions that may compromise compliance or informed consent;
- •Chronic gastrointestinal disorders with predominant diarrhea;
- •Known hypersensitivity to any study drug components; history of immunodeficiency (e.g., HIV positivity, congenital or acquired immunodeficiency disorder), or prior organ transplantation;
- •Pregnancy, lactation, or positive pregnancy test at baseline in women of childbearing potential;
- •Severe comorbidities that may interfere with treatment, including active infections (e.g., hepatitis B, hepatitis C, tuberculosis, syphilis) or any other condition deemed by the investigator to render the patient unsuitable for trial participation.
研究组 & 干预措施
Trastuzumab combined with Pertuzumab
Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and pertuzumab (840 mg IV loading dose, followed by 420 mg IV once every 3 weeks). This regimen will be repeated for a total of 18 cycles,encompassing both the preoperative and adjuvant phases.
干预措施: Trastuzumab and Pertuzumab (Drug)
Trastuzumab combined with neratinib
Trastuzumab (8 mg/kg IV loading dose, followed by 6 mg/kg IV once every 3 weeks), and neratinib 240 mg orally once daily. The trastuzumab treatment will be continued for a total of 18 cycles, encompassing both the preoperative and adjuvant phases, while neratinib will be maintained throughout the adjuvant period.
干预措施: Trastuzumab and neratinib (Drug)
结局指标
主要结局
Invasive disease free survival, IDFS
时间窗: During the 3 years after random assignment
The time from random assignment until the first occurrence of invasive disease recurrence, distant recurrence, or death from any cause.
次要结局
- Disease free survival, DFS(During the 3 years after random assignment)
- Overall survival, OS(During the 3 years after random assignment)
- Incidence and severity of adverse events(From signing the informed consent form until 28 days after completion of adjuvant treatment)
- Distant disease free survival, DDFS(During the 3 years after random assignment)
研究者
Chang Gong
Chief physician
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University